Find Anbenitamab manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

API Suppliers

0

USDMF

0

CEP/COS

0

JDMF

0

EU WC

0

KDMF

0

NDC API

0

VMF

0

Listed Suppliers

0INTERMEDIATES

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

0

FDA Orange Book

0

Europe

0

Canada

0

Australia

0

South Africa

0

Listed Dossiers

0 DRUGS IN DEVELOPMENT

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

API/FDF Prices: Book a Demo

API REF. PRICE (USD/KG)

$
$ 0

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Regulatory FDF Prices

NA

MARKET PLACE

0

API

0

FDF

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

0

News #PharmaBuzz

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Anbenitamab repodatecan asparagine modification
Molecular Formula
C220H282F2N34O86
Molecular Weight
4817  g/mol
InChI Key
JCITXTRXWKMHKE-UAWMYEJOSA-N
FDA UNII
AZ4UZN9LF2

Anbenitamab
1 2D Structure

Anbenitamab

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(2S)-4-[[(2R,3R,4R,5S,6R)-3-acetamido-5-[(2S,3R,4R,5S,6R)-3-acetamido-5-[(2S,3S,4R,5S,6R)-5-[(2R,3S,4S,5S,6R)-3-[(2S,3R,4R,5S,6R)-3-acetamido-5-[(2S,3R,4R,5R,6R)-3-[[2-[13-[4-[2-[2-[2-[2-[3-[[2-[[2-[[(2S)-1-[[2-[[2-[[(10S,23S)-10-ethyl-18-fluoro-10-hydroxy-19-methyl-5,9-dioxo-8-oxa-4,15-diazahexacyclo[14.7.1.02,14.04,13.06,11.020,24]tetracosa-1,6(11),12,14,16,18,20(24)-heptaen-23-yl]amino]-2-oxoethoxy]methylamino]-2-oxoethyl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]amino]-2-oxoethyl]amino]-3-oxopropoxy]ethoxy]ethoxy]ethoxy]ethylamino]-4-oxobutanoyl]-3,4,5,13-tetrazatetracyclo[13.4.0.02,6.07,12]nonadeca-1(19),2(6),4,7,9,11,15,17-octaen-3-yl]acetyl]amino]-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[[(2S,3S,4S,5S,6R)-3-[(2S,3R,4R,5S,6R)-3-acetamido-5-[(2S,3R,4R,5R,6R)-3-[[2-[13-[4-[2-[2-[2-[2-[3-[[2-[[2-[[(2S)-1-[[2-[[2-[[(10S,23S)-10-ethyl-18-fluoro-10-hydroxy-19-methyl-5,9-dioxo-8-oxa-4,15-diazahexacyclo[14.7.1.02,14.04,13.06,11.020,24]tetracosa-1,6(11),12,14,16,18,20(24)-heptaen-23-yl]amino]-2-oxoethoxy]methylamino]-2-oxoethyl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]amino]-2-oxoethyl]amino]-3-oxopropoxy]ethoxy]ethoxy]ethoxy]ethylamino]-4-oxobutanoyl]-3,4,5,13-tetrazatetracyclo[13.4.0.02,6.07,12]nonadeca-1(19),2(6),3,7,9,11,15,17-octaen-5-yl]acetyl]amino]-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]-3,4-dihydroxyoxan-2-yl]oxy-4-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4-hydroxy-6-[[(2R,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]amino]-2-amino-4-oxobutanoic acid
2.1.2 InChI
InChI=1S/C220H282F2N34O86/c1-10-219(310)121-68-134-166-117(81-253(134)205(304)119(121)92-324-217(219)308)164-126(40-38-111-100(3)123(221)70-128(242-166)162(111)164)238-158(281)96-320-98-232-152(275)75-230-202(302)130(66-107-26-14-12-15-27-107)240-154(277)77-228-150(273)73-226-147(270)46-50-312-54-58-316-62-64-318-60-56-314-52-48-224-145(268)42-44-160(283)251-80-110-31-19-21-33-114(110)176-169(115-34-22-24-36-132(115)251)248-250-255(176)83-156(279)244-171-183(290)179(286)136(85-257)328-208(171)337-196-141(90-262)334-212(175(187(196)294)237-106(9)267)342-201-191(298)182(289)139(88-260)331-216(201)340-199-144(335-214(194(301)192(199)299)339-197-142(91-263)332-210(173(188(197)295)235-104(7)265)338-198-143(94-322-213-193(300)189(296)178(285)102(5)326-213)327-204(170(185(198)292)234-103(6)264)246-149(272)72-125(223)207(306)307)95-323-215-200(190(297)181(288)138(87-259)330-215)341-211-174(236-105(8)266)186(293)195(140(89-261)333-211)336-209-172(184(291)180(287)137(86-258)329-209)245-157(280)84-256-177-116-35-23-25-37-133(116)252(79-109-30-18-20-32-113(109)168(177)247-249-256)161(284)45-43-146(269)225-49-53-315-57-61-319-65-63-317-59-55-313-51-47-148(271)227-74-151(274)229-78-155(278)241-131(67-108-28-16-13-17-29-108)203(303)231-76-153(276)233-99-321-97-159(282)239-127-41-39-112-101(4)124(222)71-129-163(112)165(127)118-82-254-135(167(118)243-129)69-122-120(206(254)305)93-325-218(309)220(122,311)11-2/h12-37,68-71,102,125-127,130-131,136-144,170-175,178-201,204,208-216,257-263,285-301,310-311H,10-11,38-67,72-99,223H2,1-9H3,(H,224,268)(H,225,269)(H,226,270)(H,227,271)(H,228,273)(H,229,274)(H,230,302)(H,231,303)(H,232,275)(H,233,276)(H,234,264)(H,235,265)(H,236,266)(H,237,267)(H,238,281)(H,239,282)(H,240,277)(H,241,278)(H,244,279)(H,245,280)(H,246,272)(H,306,307)/t102-,125-,126-,127-,130-,131-,136+,137+,138+,139+,140+,141+,142+,143+,144+,170+,171+,172+,173+,174+,175+,178+,179-,180-,181+,182+,183+,184+,185+,186+,187+,188+,189+,190-,191-,192+,193-,194-,195+,196+,197+,198+,199+,200-,201-,204+,208-,209-,210-,211-,212-,213+,214-,215-,216+,219-,220-/m0/s1
2.1.3 InChI Key
JCITXTRXWKMHKE-UAWMYEJOSA-N
2.2 Other Identifiers
2.2.1 UNII
AZ4UZN9LF2
2.3 Synonyms
2.3.1 Depositor-Supplied Synonyms

1. Anbenitamab Repodatecan Asparagine Modification

2.4 Create Date
2025-03-11
3 Chemical and Physical Properties
Molecular Weight 4817 g/mol
Molecular Formula C220H282F2N34O86
XLogP3-23
Hydrogen Bond Donor Count49
Hydrogen Bond Acceptor Count95
Rotatable Bond Count109
Exact Mass Da
Monoisotopic Mass Da
Topological Polar Surface Area1690
Heavy Atom Count342
Formal Charge0
Complexity12000
Isotope Atom Count0
Defined Atom Stereocenter Count57
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty